How to Get Vyleesi (Bremelanotide) in Ohio

What Is Bremelanotide and Who Is It For?

Bremelanotide is a melanocortin-4 receptor agonist approved by the FDA in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women 1. It is the only on-demand injectable therapy for low sexual desire, distinct from flibanserin (Addyi), which requires daily oral dosing 2.

How Bremelanotide Works

The drug activates melanocortin receptors in the central nervous system involved in sexual arousal pathways. In the two key RECONNECT trials (combined N=1,247), bremelanotide 1.75 mg increased the Female Sexual Function Index desire domain score by 0.53 points over placebo (P<0.001) and significantly reduced distress measured by the Female Sexual Distress Scale, Desire/Arousal/Orgasm item 3.

Who Qualifies

HSDD is defined as persistently low sexual desire causing marked personal distress that is not explained by another medical condition, psychiatric disorder, medication effect, or relationship problem 4. The FDA label limits bremelanotide to premenopausal women. The diagnosis must be clinician-confirmed, not self-reported, which means you will need a clinical evaluation before any Ohio provider writes the prescription 1.

Step-by-Step: Getting a Vyleesi Prescription in Ohio

The prescribing pathway in Ohio follows a predictable sequence. Most patients complete the process within two to three weeks.

Step 1: Choose a Qualified Prescriber

Ohio law permits physicians (MDs and DOs), nurse practitioners (NPs with prescriptive authority), and physician assistants (PAs under a collaborative agreement) to prescribe bremelanotide 5. Any of these clinician types can evaluate for HSDD and initiate therapy. In practice, OB/GYNs, sexual medicine specialists, and endocrinologists are the most common prescribers.

Step 2: Complete a Clinical Evaluation

Your provider will screen for HSDD using a validated tool such as the Decreased Sexual Desire Screener (DSDS) 6. This brief questionnaire helps distinguish HSDD from desire changes caused by depression, relationship factors, or medication side effects. A menstrual and medication history is standard. Bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease because it can transiently raise blood pressure 1.

Step 3: Baseline Labs and Vitals

Before the first prescription, most Ohio providers will order a focused lab panel. There is no single mandated panel, but the ISSWSH process-of-care algorithm recommends checking thyroid function (TSH), prolactin, and a metabolic panel to exclude secondary causes of low desire 7. Blood pressure must be documented as controlled (below 140/90 mmHg per the FDA label) before bremelanotide is prescribed 1. A pregnancy test is standard practice for premenopausal patients starting any new medication with limited pregnancy data.

Step 4: Prescription and Pharmacy Routing

Once cleared, your prescriber sends the prescription to a specialty pharmacy or, in some cases, a retail pharmacy that stocks the autoinjector. We discuss pharmacy options below.

Telehealth Access in Ohio

Ohio permits telehealth prescribing of bremelanotide. After COVID-era expansions, Ohio codified permanent telehealth authority under Ohio Revised Code § 4743.09, allowing clinicians to establish a provider-patient relationship via synchronous audio-video visit 8.

What a Telehealth Visit Looks Like

A typical HSDD telehealth consultation lasts 20 to 30 minutes. The provider reviews your medical history, screens for HSDD using the DSDS, and discusses contraindications. Labs can be completed at any Ohio draw site (LabCorp, Quest, or hospital outpatient labs) before or after the visit. Blood pressure must be self-reported or measured at a local pharmacy kiosk and documented. Some telehealth platforms specializing in women's sexual health will ship a home blood-pressure cuff with the intake kit.

Choosing a Telehealth Platform

National telehealth platforms that serve Ohio and carry bremelanotide on formulary include HealthRX, Lemonaid, and several sexual-medicine specialty clinics with multi-state licensing. Confirm that the prescriber holds an active Ohio medical license and that the platform coordinates specialty pharmacy fulfillment.

Ohio Pharmacy Options for Vyleesi

Getting the physical medication is one of the most common friction points. Brand-name Vyleesi is distributed through specialty pharmacies; not every corner pharmacy stocks it.

Specialty Pharmacy Fulfillment

The majority of Vyleesi prescriptions in Ohio are filled through specialty pharmacies such as Alto, Optum Specialty, or Accredo. These pharmacies handle prior authorization paperwork, ship temperature-controlled autoinjectors directly to your home, and provide injection training by phone 9.

503A Compounding Pharmacies

Ohio-licensed 503A pharmacies can compound bremelanotide for an individual patient prescription. This pathway bypasses brand-name pricing entirely but requires the prescriber to write for compounded bremelanotide rather than brand Vyleesi. Ohio Board of Pharmacy regulations require the 503A facility to hold a valid Terminal Distributor of Dangerous Drugs license 10. Compounded bremelanotide typically arrives as a multi-dose vial rather than an autoinjector, so patients will need syringes and may benefit from a brief injection tutorial.

Retail Pharmacy Availability

A limited number of retail pharmacies (CVS, Walgreens) can order Vyleesi, but lead times of 3 to 7 business days are common because the drug is not routinely stocked. If your insurer requires a specific pharmacy network, confirm network participation before the prescription is transmitted.

Insurance and Cost in Ohio

Vyleesi carries a wholesale acquisition cost of roughly $950 per carton of four autoinjectors. Out-of-pocket cost depends heavily on your plan.

Commercial Insurance

Most Ohio commercial plans (Anthem, Medical Mutual, UnitedHealthcare, Aetna) classify Vyleesi as a specialty-tier drug requiring prior authorization. PA documentation typically includes: confirmed HSDD diagnosis (ICD-10 code F52.0), documentation that desire distress is not attributable to a medical or psychiatric comorbidity, and a notation that the patient is premenopausal 11. Some plans also require a trial-and-failure of flibanserin before approving bremelanotide. With approved PA, commercial copays generally range from $50 to $150 per fill through specialty pharmacy.

Ohio Medicaid

Ohio Medicaid does not cover Vyleesi. The Ohio Department of Medicaid formulary excludes bremelanotide, reflecting the drug's narrow indication and the state's cost-containment approach to specialty medications. Medicaid-enrolled patients in Ohio may access bremelanotide through the manufacturer's patient assistance program or through a compounded formulation at reduced cost.

Manufacturer Savings and Patient Assistance

Palatin Technologies offers a copay savings card that reduces out-of-pocket cost to as low as $0 for eligible commercially insured patients. An income-based patient assistance program also exists for uninsured or underinsured women. Eligibility typically requires household income below 400% of the federal poverty level.

Prior Authorization: What Ohio Insurers Require

Prior authorization is the single most common barrier to timely access. Knowing what the insurer needs in advance can shave a week off the process.

Required Documentation

A standard Ohio PA request for bremelanotide includes five elements: (1) the prescriber's clinical notes confirming HSDD diagnosis per DSM-5 criteria 4, (2) documentation that the patient is premenopausal, (3) a blood pressure reading below 140/90, (4) a statement that the condition causes clinically significant distress, and (5) notation of any prior pharmacotherapy trials (some plans require flibanserin failure) 12.

Timeline and Appeals

Ohio insurers must respond to a standard PA request within 72 hours. Urgent requests require a 24-hour turnaround. If denied, your prescriber can file a peer-to-peer review and, if that fails, a formal appeal. According to Ohio Department of Insurance data, first-level appeals overturn roughly 40% to 50% of specialty drug denials.

Peer-to-Peer Tips

During peer-to-peer review, emphasize the RECONNECT trial data: bremelanotide produced a statistically significant 0.53-point increase in FSFI desire score over placebo across both studies, and 35% of treated patients reported a meaningful improvement in satisfying sexual events versus 31% on placebo 3. Clinicians find it useful to note that bremelanotide acts through a distinct mechanism (melanocortin receptor agonism) compared to flibanserin (5-HT1A agonism/5-HT2A antagonism), making cross-class switching clinically justified after flibanserin failure 13.

Safety Monitoring After Starting Bremelanotide

Once your Ohio provider prescribes bremelanotide, ongoing monitoring is straightforward but non-optional.

Blood Pressure

The most clinically significant adverse effect is transient hypertension. In the RECONNECT trials, bremelanotide increased systolic blood pressure by an average of 2.5 mmHg and diastolic by 1.2 mmHg, peaking about 2 to 3 hours post-dose and resolving within 12 hours 3. The FDA label recommends against use in patients with uncontrolled hypertension or cardiovascular disease 1. Ohio prescribers typically recheck blood pressure at the first follow-up (4 to 6 weeks) and then every 6 to 12 months.

Nausea

Nausea is the most common adverse event, reported by 40% of bremelanotide-treated patients in the RECONNECT trials versus 1% on placebo 3. It is typically mild, self-limiting, and decreases with repeated use. The FDA label notes that 13% of patients who experienced nausea used an antiemetic 1. Taking the injection on a partially full stomach or pre-treating with ondansetron 4 mg are strategies Ohio prescribers commonly recommend.

Skin Hyperpigmentation

Bremelanotide activates melanocortin-1 receptors, which can cause focal darkening of the gums, face, or breasts with repeated dosing. The FDA label warns about this effect, noting it occurred in up to 1% of trial participants and may not fully reverse after discontinuation 1. Patients should report any new pigmentation changes at follow-up visits.

Transferring a Vyleesi Prescription to Ohio

If you are relocating to Ohio from another state, your existing Vyleesi prescription can be transferred. Ohio Board of Pharmacy rules permit interstate prescription transfers for non-controlled substances 14. Bremelanotide is not a scheduled controlled substance, so the transfer process is the same as for any non-controlled specialty medication. Your current pharmacy calls the receiving Ohio pharmacy to transfer the prescription record. If your new Ohio provider wants to re-evaluate before continuing therapy, a single telehealth visit is sufficient to reauthorize the prescription under an Ohio license.

How Long Until You Receive Vyleesi in Ohio?

Timeline varies by pathway.

Telehealth with specialty pharmacy, commercial insurance: 10 to 21 days from initial visit to medication in hand. The bottleneck is PA turnaround (up to 72 hours standard) plus specialty pharmacy shipping (2 to 5 business days).

In-person prescriber, no PA needed (cash pay or 503A compound): 5 to 10 days. Labs and evaluation can happen in one visit; the pharmacy compounds or ships within a few business days.

Telehealth with 503A compounding: 7 to 14 days. Lab turnaround and compounding time are the two variables.

Rush shipping is available from most specialty pharmacies for an additional fee if the PA is already approved.

Ohio-Specific Regulatory Notes

Ohio does not impose any state-level restrictions on bremelanotide beyond federal FDA labeling requirements. The Ohio Board of Pharmacy's 503A compounding regulations align with federal standards under the Drug Quality and Security Act (DQSA) 15. Ohio prescribers should be aware that the state's collaborative practice agreements for PAs require physician co-signature on the initial specialty prescription in some health systems, though NPs with full practice authority in Ohio can prescribe independently.